Adma Biologics Inc. (NASDAQ:ADMA)’s share price traded up 6.4% during trading on Friday . The company traded as high as $6.49 and last traded at $6.49, with a volume of 66,052 shares traded. The stock had previously closed at $6.10.

ADMA has been the subject of a number of recent research reports. Raymond James Financial Inc. lowered Adma Biologics from a “strong-buy” rating to a “market perform” rating in a research note on Monday, August 1st. Maxim Group lowered Adma Biologics from a “buy” rating to a “hold” rating in a research note on Monday, August 1st.

The company’s market capitalization is $83.63 million. The stock’s 50 day moving average price is $6.60 and its 200-day moving average price is $6.40.

Adma Biologics (NASDAQ:ADMA) last issued its earnings results on Tuesday, August 9th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.39) by $0.11. Equities research analysts expect that Adma Biologics Inc. will post ($1.49) EPS for the current year.

ADMA Biologics, Inc is a biopharmaceutical company that develops and manufactures specialty plasma-based biologics for the treatment and prevention of certain infectious diseases. The company’s targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.